BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-03-17

Last Posted Date: 2016-12-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 81332

Registration Number: NCT01088321

Abatacept Pregnancy Exposure Registry

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: No Interventions

First Posted Date: 2010-03-16

Last Posted Date: 2023-07-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT01087125

Locations: 🇺🇸
Bristol-Myers Squibb, Active, Princeton, New Jersey, United States

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: BMS-908662
Drug: Cetuximab

First Posted Date: 2010-03-15

Last Posted Date: 2016-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 17

Registration Number: NCT01086267

Locations: 🇺🇸
Oncology Research Associates D/B/A, Scottsdale, Arizona, United States
🇨🇦
Local Institution, Ottawa, Ontario, Canada
🇺🇸
Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States

Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

Phase 1

Terminated

Conditions: Hypercholesterolemia
Atherosclerosis

Interventions: Drug: 0.9% sodium chloride injection solution
Drug: BMS-844421

First Posted Date: 2010-03-08

Last Posted Date: 2011-01-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT01082562

Locations: 🇩🇪
Local Institution, Berlin, Germany

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: BMS-708163

First Posted Date: 2010-03-03

Last Posted Date: 2011-02-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT01079819

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸
Iberica Clinical Research Center, Eatontown, New Jersey, United States

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

Phase 3

Completed

Conditions: Chronic Hepatitis B Virus, Pediatric

Interventions: Drug: Placebo
Drug: Entecavir

First Posted Date: 2010-03-03

Last Posted Date: 2019-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 180

Registration Number: NCT01079806

Locations: 🇺🇸
Children'S National Medical Center, Washington, District of Columbia, United States
🇺🇸
Shah, Uzma, Boston, Massachusetts, United States
🇺🇸
Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States

and more 13 locations

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: BMS-690514
Drug: Lapatinib
Drug: Letrozole

First Posted Date: 2010-02-15

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4

Registration Number: NCT01068704

Locations: 🇺🇸
Texas Oncology-Abilene, Abilene, Texas, United States
🇺🇸
Texas Oncology-Beaumont, Beaumont, Texas, United States
🇺🇸
Us Oncology Central Pharmacy, Fort Worth, Texas, United States

and more 2 locations

Drug Interaction Oral Contraceptive Pill (OCP)

Phase 1

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Ortho Tri-Cyclen®
Drug: BMS-650032

First Posted Date: 2010-02-05

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT01063023

Locations: 🇺🇸
Pra International, Lenexa, Kansas, United States

Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment

Phase 3

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Entecavir
Drug: Tenofovir

First Posted Date: 2010-02-05

Last Posted Date: 2014-12-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 144

Registration Number: NCT01063036

Locations: 🇪🇸
Local Institution, Valencia, Spain

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: BMS-770767
Drug: Placebo

First Posted Date: 2010-01-28

Last Posted Date: 2012-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 81

Registration Number: NCT01058083

Locations: 🇺🇸
Cetero Research - San Antonio, San Antonio, Texas, United States
🇨🇦
Local Institution, Montreal, Quebec, Canada
🇺🇸
Harrell, Robert, Little Rock, Arkansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy